N/A
Completed N=7,304
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
Source: ClinicalTrials.gov NCT05643885 ↗Enrolled (actual)
7,304
Serious AEs
—
Results posted
Oct 2025
Primary outcomePrimary: Mean All-Cause Healthcare Costs Per Participant Per Month (PPPM) for VTE Events — 16420; 21312 USD per participant per month — p=<0.0001
Summary
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean All-Cause Healthcare Costs Per Participant Per Month (PPPM) for VTE Events |
16420; 21312 | <0.0001 sig |
| PRIMARY Mean All-Cause Healthcare Outpatient Pharmacy Costs PPPM for VTE Events |
2452; 2654 | <0.0001 sig |
| PRIMARY Mean All-Cause Healthcare Outpatient Medical Costs PPPM for VTE Events |
8028; 10042 | <0.0001 sig |
| PRIMARY Mean All-Cause Healthcare Hospitalization Costs PPPM for VTE Events |
5940; 8616 | <0.0001 sig |
| PRIMARY Mean All-Cause Healthcare Costs PPPM for Recurrent VTE Events |
11277; 13074 | =0.2303 |
| PRIMARY Mean All-Cause Healthcare Outpatient Medical Costs PPPM for Recurrent VTE Events |
827; 884 | =0.7403 |
| PRIMARY Mean All-Cause Healthcare Hospitalization Costs PPPM for Recurrent VTE Events |
10450; 12190 | =0.2414 |
| PRIMARY Mean All-Cause Healthcare Costs PPPM for Major Bleeding Related VTE Events |
19384; 22719 | =0.2592 |
| PRIMARY Mean All-Cause Outpatient Medical Costs PPPM for Major Bleeding Related VTE Events |
268; 346 | =0.4837 |
| PRIMARY Mean All-Cause Hospitalization Costs PPPM for Major Bleeding Related VTE Events |
19116; 22373 | =0.1355 |
| PRIMARY Mean All-Cause Healthcare Costs PPPM for Clinically Relevant Non-Major (CRNM) Bleeding Related VTE Events |
4883; 5227 | =0.6066 |
| PRIMARY Mean All-Cause Outpatient Medical Costs PPPM for CRNM Bleeding Related VTE Events |
431; 483 | =0.3795 |
| PRIMARY Mean All-Cause Hospitalization Costs PPPM for CRNM Bleeding Related VTE Events |
4452; 4744 | =0.6618 |
| SECONDARY Mean Number of Hospitalizations Per Participant Per Month (PPPM) for VTE Events |
0.4; 0.4 | =0.2337 |
| SECONDARY Mean Number of Outpatient Medical Visits PPPM for VTE Events |
3.0; 3.5; 0.2; 0.2; 5.6; 8.1 | <0.0001 sig |
| SECONDARY Mean Number of Prescription Fills PPPM for VTE Events |
5.0; 5.6 | <0.0001 sig |
| SECONDARY Mean Number of Hospitalizations PPPM for Recurrent VTE Events |
0.6; 0.6 | =0.7290 |
| SECONDARY Mean Number of Outpatient Medical Visits PPPM for Recurrent VTE Events |
0.7; 0.6; 0.0; 0.0; 0.6; 0.8 | =0.3686 |
| SECONDARY Mean Number of Hospitalizations PPPM for Major Bleeding Related VTE Events |
0.6; 0.6 | =0.9796 |
| SECONDARY Mean Number of Outpatient Medical Visits PPPM for Major Bleeding Related VTE Events |
0.3; 0.5; 0.0; 0.0; 0.4; 0.3 | =0.0379 sig |
| SECONDARY Mean Number of Hospitalizations PPPM for CRNM Bleeding Related VTE Events |
0.5; 0.5 | =0.5660 |
| SECONDARY Mean Number of Outpatient Medical Visits PPPM for CRNM Bleeding Related VTE Events |
0.3; 0.4; 0.1; 0.1; 0.7; 0.9 | =0.0425 sig |
Eligibility Criteria
Inclusion Criteria
- Venous thromboembolism (VTE) diagnosis between January 1 2017 and October 31 2021
- Evidence of active cancer
- At least 1 claim for apixaban or low molecular weight heparin (LMWH)
- Age 18 years or older
Exclusion Criteria
- diagnosis of atrial fibrillation/flutter
- procedure for mechanical heart valve or inferior vena cava filter
- VTE diagnosis in the baseline period
- anticoagulant therapy in the baseline period
- pregnancy
Data sourced from ClinicalTrials.gov (NCT05643885). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.